Yang et al. reported at the 2020 ASH Annual Meeting data on an anti-CD19/CD22 dual CAR-T (GC022F) therapy in patients with B-ALL based on a novel manufacturing platform, from a phase I clinical study in treating patients with B-ALL [59]. Here, CD19 is linked to acute lymphoblastic leukemia.